Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Obesity
Biotech
Lilly rounds out orforglipron data ahead of obesity filings
With a complete weight loss data set in hand, Lilly is eyeing regulatory filings for orforglipron and thinks approvals could start arriving next year.
Fraiser Kansteiner
Sep 17, 2025 9:00am
Novo pushes ahead with amylin after seeing ph. 3 tolerability
Sep 16, 2025 8:12am
Fierce Pharma
Novo charts major restructuring, layoffs under new CEO
Sep 10, 2025 8:41am
Lilly ends 2 midstage trials for oral GLP-1 drug naperiglipron
Sep 2, 2025 4:32am
Novo seeks obesity refresh with $550M Replicate deal
Aug 28, 2025 7:00am
Lilly's oral GLP-1 charts 10.5% weight loss in diabetic patients
Aug 26, 2025 6:45am